Literature DB >> 26011311

Automated production at the curie level of no-carrier-added 6-[(18)F]fluoro-L-dopa and 2-[(18)F]fluoro-L-tyrosine on a FASTlab synthesizer.

C Lemaire1, L Libert1, X Franci2, J-L Genon1, S Kuci2, F Giacomelli1, A Luxen1.   

Abstract

An efficient, fully automated, enantioselective multi-step synthesis of no-carrier-added (nca) 6-[(18)F]fluoro-L-dopa ([(18)F]FDOPA) and 2-[(18)F]fluoro-L-tyrosine ([(18)F]FTYR) on a GE FASTlab synthesizer in conjunction with an additional high- performance liquid chromatography (HPLC) purification has been developed. A PTC (phase-transfer catalyst) strategy was used to synthesize these two important radiopharmaceuticals. According to recent chemistry improvements, automation of the whole process was implemented in a commercially available GE FASTlab module, with slight hardware modification using single use cassettes and stand-alone HPLC. [(18)F]FDOPA and [(18)F]FTYR were produced in 36.3 ± 3.0% (n = 8) and 50.5 ± 2.7% (n = 10) FASTlab radiochemical yield (decay corrected). The automated radiosynthesis on the FASTlab module requires about 52 min. Total synthesis time including HPLC purification and formulation was about 62 min. Enantiomeric excesses for these two aromatic amino acids were always >95%, and the specific activity of was >740 GBq/µmol. This automated synthesis provides high amount of [(18)F]FDOPA and [(18)F]FTYR (>37 GBq end of synthesis (EOS)). The process, fully adaptable for reliable production across multiple PET sites, could be readily implemented into a clinical good manufacturing process (GMP) environment.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  2-[18F]fluoro- l-tyrosine; F-18, [18F]FDOPA; GMP; automation; solid-phase extraction

Mesh:

Substances:

Year:  2015        PMID: 26011311     DOI: 10.1002/jlcr.3291

Source DB:  PubMed          Journal:  J Labelled Comp Radiopharm        ISSN: 0362-4803            Impact factor:   1.921


  9 in total

1.  One-pot synthesis of high molar activity 6-[18F]fluoro-l-DOPA by Cu-mediated fluorination of a BPin precursor.

Authors:  Andrew V Mossine; Sean S Tanzey; Allen F Brooks; Katarina J Makaravage; Naoko Ichiishi; Jason M Miller; Bradford D Henderson; Marc B Skaddan; Melanie S Sanford; Peter J H Scott
Journal:  Org Biomol Chem       Date:  2019-09-19       Impact factor: 3.876

2.  Performing radiosynthesis in microvolumes to maximize molar activity of tracers for positron emission tomography.

Authors:  Maxim E Sergeev; Mark Lazari; Federica Morgia; Jeffrey Collins; Muhammad Rashed Javed; Olga Sergeeva; Jason Jones; Michael E Phelps; Jason T Lee; Pei Yuin Keng; R Michael van Dam
Journal:  Commun Chem       Date:  2018-03-22

3.  Could 68Ga-somatostatin analogues be an important alternative to 18F-DOPA PET/CT in pediatrics?

Authors:  Arnoldo Piccardo; Giorgio Treglia
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-27       Impact factor: 9.236

4.  Synthesis of high-molar-activity [18F]6-fluoro-L-DOPA suitable for human use via Cu-mediated fluorination of a BPin precursor.

Authors:  Andrew V Mossine; Sean S Tanzey; Allen F Brooks; Katarina J Makaravage; Naoko Ichiishi; Jason M Miller; Bradford D Henderson; Thomas Erhard; Christian Bruetting; Marc B Skaddan; Melanie S Sanford; Peter J H Scott
Journal:  Nat Protoc       Date:  2020-04-08       Impact factor: 13.491

5.  Synthesis of [18F]PS13 and Evaluation as a PET Radioligand for Cyclooxygenase-1 in Monkey.

Authors:  Carlotta Taddei; Cheryl L Morse; Min-Jeong Kim; Jeih-San Liow; Jose Montero Santamaria; Andrea Zhang; Lester S Manly; Paolo Zanotti-Fregonara; Robert L Gladding; Sami S Zoghbi; Robert B Innis; Victor W Pike
Journal:  ACS Chem Neurosci       Date:  2021-01-25       Impact factor: 5.780

Review 6.  Amino acid PET and MR perfusion imaging in brain tumours.

Authors:  Christian P Filss; Francesco Cicone; Nadim Jon Shah; Norbert Galldiks; Karl-Josef Langen
Journal:  Clin Transl Imaging       Date:  2017-03-13

7.  Improved GMP-compliant multi-dose production and quality control of 6-[18F]fluoro-L-DOPA.

Authors:  G Luurtsema; H H Boersma; M Schepers; A M T de Vries; B Maas; R Zijlma; E F J de Vries; P H Elsinga
Journal:  EJNMMI Radiopharm Chem       Date:  2016-04-04

8.  Gene Therapy for Parkinson's Disease: Preclinical Evaluation of Optimally Configured TH:CH1 Fusion for Maximal Dopamine Synthesis.

Authors:  Romina Aron Badin; Katie Binley; Nadja Van Camp; Caroline Jan; Jeanne Gourlay; Camille Robert; Pauline Gipchtein; Audrey Fayard; Hannah Stewart; G Scott Ralph; Yatish Lad; Michelle Kelleher; Julie Loader; Koichi Hosomi; Stéphane Palfi; Kyriacos A Mitrophanous; Philippe Hantraye
Journal:  Mol Ther Methods Clin Dev       Date:  2019-07-16       Impact factor: 6.698

Review 9.  Nucleophilic Synthesis of 6-l-[18F]FDOPA. Is Copper-Mediated Radiofluorination the Answer?

Authors:  Raisa N Krasikova
Journal:  Molecules       Date:  2020-09-23       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.